Login Register Cart 0
Generic placeholder image

Current Pharmaceutical Design

Editor-in-Chief

ISSN (Print): 1381-6128
ISSN (Online): 1873-4286

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Treatment of Metastatic Renal Cell Carcinoma with Checkpoint Inhibitors in Clinical Practice in the Volga-Ural Region of the Eurasian Continent

Author(s): Radmir R. Rakhimov, Aleksandr V. Sultanbaev, Adel A. Izmailov, Konstantin V. Menshikov, Vadim M. Zabelin, Albert A. Izmailov, Gulshat R. Gilyazova, Svetlana M. Izmailova, Ksenia S. Bakhtiyarova, Angelina A. Izmailova and Irina R. Gilyazova*

Volume 29, Issue 41, 2023

Published on: 30 November, 2023

Page: [3312 - 3323] Pages: 12

DOI: 10.2174/0113816128262498231122072050

Price: $65

conference banner
Abstract

Introduction: Renal cancer ranks 10th in the mortality structure of the Russian Federation. The introduction of checkpoint inhibitors has changed the paradigm of treatment of patients with malignant neoplasms.

Method: Data from clinical trials have shown good progression-free median and median overall survival. Each cancer center has been accumulating its own experience in treating patients with renal cell cancer by applying modern target drugs and immunotherapy.

Result: In routine clinical practice, oncologists do not get the results that have been demonstrated in clinical trials when evaluating the effectiveness of the therapy.

Conclusion: In this single-center clinical study, we discuss the results of using nivolumab as mono-therapy and the combination of nivolumab with ipilimumab in metastatic renal parenchyma cancer patients.

Keywords: Oncology, renal cancer, immunotherapy, checkpoint inhibitors, nivolumab, ipilimumab.

« Previous Next »
[1]
Kaprin AD, Starinskiy VV, Shakhzadova AO. Malignant neoplasms in Russia in 2021 (morbidity and mortality). Moscow: Herzen Moscow Research Oncological Institute-branch of the National Medical Research Center of Radiology 2022; 252
[2]
Motzer RJ, Tannir NM, McDermott DF, et al. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med 2018; 378(14): 1277-90.
[http://dx.doi.org/10.1056/NEJMoa1712126] [PMID: 29562145]
[3]
Albiges L, Tannir NM, Burotto M, et al. Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: Extended 4-year follow-up of the phase III CheckMate 214 trial. ESMO Open 2020; 5(6): e001079.
[http://dx.doi.org/10.1136/esmoopen-2020-001079] [PMID: 33246931]
[4]
Motzer RJ, Escudier B, George S, et al. Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long-term follow-up of the randomized, open-label, phase 3 CheckMate 025 trial. Cancer 2020; 126(18): 4156-67.
[http://dx.doi.org/10.1002/cncr.33033] [PMID: 32673417]
[5]
McDermott DF, Drake CG, Sznol M, et al. Survival, durable response, and long-term safety in patients with previously treated advanced renal cell carcinoma receiving nivolumab. J Clin Oncol 2015; 33(18): 2013-20.
[http://dx.doi.org/10.1200/JCO.2014.58.1041] [PMID: 25800770]
[6]
Vogelzang N, McFarlane J, Kochenderfer M, et al. Efficacy and safety of nivolumab in patients with non-clear cell renal cell carcinoma: Results from the phase 3b/4 CheckMate 374 study. 2019 Genitourinary Cancers Symposium. February 14-16, 2019; San Francisco, CA.
[http://dx.doi.org/10.1200/JCO.2019.37.7_suppl.562]
[7]
Chahoud J, Msaouel P, Campbell MT, et al. Nivolumab for the treatment of patients with metastatic non-clear cell renal cell carcinoma (nccRCC): A single-institutional experience and literature meta-analysis. Oncologist 2020; 25(3): 252-8.
[http://dx.doi.org/10.1634/theoncologist.2019-0372] [PMID: 32162795]
[8]
McFarlane J, Olsen M, Molina A, et al. Safety of nivolumab in patients with clear cell or non–clear cell renal cell carcinoma: Results from the phase IIIb/IV CheckMate 374 study. 16th International Kidney Cancer Symposium. November 3–4, 2017; Miami, FL.
[9]
Tykodi SS, Gordan LN, Alter RS, et al. Safety and efficacy of nivolumab plus ipilimumab in patients with advanced non-clear cell renal cell carcinoma: Results from the phase 3b/4 CheckMate 920 trial. J Immunother Cancer 2022; 10(2): e003844.
[http://dx.doi.org/10.1136/jitc-2021-003844] [PMID: 35210307]
[10]
Gulati S, Philip E, Salgia S, Pal SK. Evolving treatment paradigm in metastatic non clear cell renal cell carcinoma. Cancer Treat Res Commun 2020; 23: 100172.
[http://dx.doi.org/10.1016/j.ctarc.2020.100172] [PMID: 32252014]
[11]
Koshkin VS, Barata PC, Zhang T, et al. Clinical activity of nivolumab in patients with non-clear cell renal cell carcinoma. J Immunother Cancer 2018; 6(1): 9.
[http://dx.doi.org/10.1186/s40425-018-0319-9] [PMID: 29378660]
[12]
Motzer RJ, Rini BI, McDermott DF, et al. Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: Extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial. Lancet Oncol 2019; 20(10): 1370-85.
[http://dx.doi.org/10.1016/S1470-2045(19)30413-9] [PMID: 31427204]
[13]
McKay RR, Bossé D, Xie W, et al. The clinical activity of PD-1/ PD-L1 inhibitors in metastatic non-clear cell renal cell carcinoma. Cancer Immunol Res 2018; 6(7): 758-65.
[http://dx.doi.org/10.1158/2326-6066.CIR-17-0475] [PMID: 29748390]
[14]
Nosov DA, Alekseev BY, Volkova MI, Gladkov OA, Popov AM, Kharkevich GY. Practical recommendations for the drug treatment of renal cell carcinoma. Malignant Tumors: Prac Guidelines 2020; 10: 31.
[15]
Gupta R, Ornstein MC, Li H, et al. Clinical activity of ipilimumab plus nivolumab in patients with metastatic non-clear cell renal cell carcinoma. Clin Genitourin Cancer 2020; 18(6): 429-35.
[http://dx.doi.org/10.1016/j.clgc.2019.11.012] [PMID: 32800717]
[16]
Emamekhoo H, Olsen MR, Carthon BC, et al. Safety and efficacy of nivolumab plus ipilimumab in patients with advanced renal cell carcinoma with brain metastases: CheckMate 920. Cancer 2022; 128(5): 966-74.
[http://dx.doi.org/10.1002/cncr.34016] [PMID: 34784056]
[17]
Buonerba C, Dolce P, Iaccarino S, et al. Outcomes associated with first- line anti-PD- 1/ PD- L1 agents vs. sunitinib in patients with sarcomatoid renal cell carcinoma: A systematic review and meta-analysis. Cancers (Basel) 2020; 12(2): 408.
[http://dx.doi.org/10.3390/cancers12020408] [PMID: 32050629]
[18]
Tannir NM, Frontera OA, Hammers HJ, et al. Thirty-month follow-up of the phase III CheckMate 214 trial of first-line nivolumab + ipilimumab (N+I) or sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC). J Clin Oncol 2019; 37(7_suppl): 547.
[http://dx.doi.org/10.1200/JCO.2019.37.7_suppl.547]
[19]
Auvray M, Auclin E, Barthelemy P, et al. Second-line targeted therapies after nivolumab-ipilimumab failure in metastatic renal cell carcinoma. Eur J Cancer 2019; 108: 33-40.
[http://dx.doi.org/10.1016/j.ejca.2018.11.031] [PMID: 30616146]
[20]
Hammers HJ, Plimack ER, Infante JR, et al. Safety and effi-cacy of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma: The checkmate 016 study. J Clin Oncol 2017; 35(34): 3851-8.
[http://dx.doi.org/10.1200/JCO.2016.72.1985] [PMID: 28678668]
[21]
Abovich YA, Sarzhevsky VO, Bronov OY, Kolesnikova DS. A case of drug-induced pneumonitis in a patient with metastatic kidney cancer after the end of nivolumab treatment. Russ Electron J Radiol 2020; 10(1): 271-8.
[http://dx.doi.org/10.21569/2222-7415-2020-10-1-271-278]
[22]
Pal SK, Karam JA, Bergerot P, Agarwal N. Developing a clear path forward for non-clear-cell renal carcinoma. J Clin Oncol 2016; 34(32): 3825-6.
[http://dx.doi.org/10.1200/JCO.2016.69.3572] [PMID: 27601540]
[23]
Hammers HJ, Plimack ER, Infante JR, et al. Safety and efficacy of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma. J Clin Oncol 2017; 35(34): 3851-8.
[http://dx.doi.org/10.1200/JCO.2016.72.1985] [PMID: 28678668]
[24]
Matveev VB. Nivolumab - The new standard in the treatment of metastatic kidney cancer. Oncourology 2017; 13(3): 3851-8.
[http://dx.doi.org/10.17650/1726-9776-2017-13-3-18-26]
[25]
Kushlinskii NE, Fridman MV, Morozov AA, Gershtein ES, Kadagidze ZG, Matveev VB. Modern approaches to kidney cancer immunotherapy. Cancer Urol 2018; 14(2): 54-67.
[http://dx.doi.org/10.17650/1726-9776-2018-14-2-54-67]
[26]
Timofeev IV. Nivolumab: 5 years from the day of international registration of immunotherapy of metastatic kidney cancer. Malignant tumors 2020; 10(24): 21-9.
[27]
Matveev VB, Volkova MI, Olshanskaya AS. Repositioning of immunotherapy in advanced kidney cancer: Nivolumab in combination with ipilimumab in the 1st line of treatment. Oncourology 2019; 15(1): 125-30.
[http://dx.doi.org/10.17650/1726-9776-2019-15-1-125-130]
[28]
Manley BJ, Hakimi AA. Molecular profiling of renal cell carcinoma. Curr Opin Urol 2016; 26(5): 383-7.
[http://dx.doi.org/10.1097/MOU.0000000000000307] [PMID: 27467134]
[29]
Sayapina MS, Savelov NA, Lyubimova NV, Timofeev YuS, Nosov DA. Potential biomarkers of the efficacy of nivolumab therapy in metastatic renal cell carcinoma. Oncourology 2018; 14(1): 16-27.

Rights & Permissions Print Cite
Article Metrics
23
2
Wayfinder Image
© 2024 Bentham Science Publishers | Privacy Policy